98%
921
2 minutes
20
Study Objective: This study sought to assess the predictive value of HFPEF score in patients with COVID-19.
Design: Retrospective study.
Setting: Rush University Medical Center.
Participants: A total of 1682 patients had an echocardiogram in the year preceding their COVID-19 admission with a preserved ejection fraction (≥50%). A total of 156 patients met inclusion criteria.
Interventions: Patients were divided into HFPEF into low (0-2), intermediate (3-5), and high (6-9) score HFPEF groups and outcomes were compared.
Main Outcome Measures: Adjusted multivariable logistic regression models evaluated the association between HFPEF score group and a composite outcome for severe COVID-19 infection consisting of (1) 60-day mortality or illness requiring (2) intensive care unit, (3) intubation, or (4) non-invasive positive pressure ventilation.
Results: High HFPEF scores were at increased risk for severe COVID-19 infection when compared intermediate to HFPEF score groups (OR 2.18 [CI: 1.01-4.80]; = 0.049) and low HFPEF score groups (OR 2.99 [CI: 1.22-7.61]; < 0.05). There was no difference in outcome between intermediate HFPEF scores (OR 1.34 [CI: 0.59-3.16]; = 0.489) and low HFPEF score.
Conclusions: Patients with a high HFPEF score were at increased risk for severe COVID-19 infection when compared to patients with an intermediate or low HFPEF score regardless of regardless of coronary artery disease and chronic kidney disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887956 | PMC |
http://dx.doi.org/10.1016/j.ahjo.2022.100111 | DOI Listing |
J Am Coll Cardiol
September 2025
Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Background: Incretin-based therapies are used to treat type 2 diabetes and obesity, but the presence of diabetes diminishes the magnitude of weight loss produced by these drugs in people with obesity. It is not known whether this attenuated weight change is relevant to the clinical benefits of these drugs in heart failure.
Objectives: The goal of this study was to assess the influence of diabetes on the efficacy and safety of tirzepatide in the SUMMIT trial.
Arq Bras Cardiol
August 2025
Instituto Dante Pazzanese de Cardiologia, São Paulo, SP - Brasil.
ESC Heart Fail
September 2025
Robertson Centre for Biostatistics and Primary Care and General Practice, School of Health and Well Being, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Aims: The study aims to evaluate the effects of exercise-based cardiac rehabilitation (ExCR) on the health-related quality of life (HRQoL) in people with heart failure preserved ejection fraction (HFpEF).
Methods: This study is a systematic review and meta-analysis. Six bibliographic databases (Medline, Embase, Web of Science, Cumulative Index of Nursing and Allied Health Literature, Cochrane CENTRAL and China National Knowledge Infrastructure database) were searched to April 2024 for randomized controlled trials (RCTs), involving adults with HFpEF undertaking ExCR compared with no exercise control.
JACC Adv
August 2025
University of Groningen, University Medical Centre Groningen, Department of Cardiology, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, The Netherlands. Electronic address:
Background: EAT may play a role in the pathophysiology of HFpEF.
Objectives: This study examined associations between increased epicardial adipose tissue (EAT), functional status and invasive exercise hemodynamics in a large cohort of heart failure (HF) with preserved ejection fraction (HFpEF) patients.
Methods: All patients underwent echocardiography, 6-minute walk distance (MWD) test, Kansas City Cardiomyopathy Questionnaire (KCCQ) and invasive hemodynamic assessment at rest and during ergometry.
JAMA
August 2025
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Importance: Heart failure with preserved ejection fraction (HFpEF) is a major cause of hospitalization, often occurring in patients with cardiometabolic comorbidities such as obesity and type 2 diabetes. Although early trials of semaglutide and tirzepatide have shown promising results in improving symptoms, those findings were based on few clinical events, leaving treatment recommendations uncertain.
Objective: To evaluate the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic HFpEF in clinical practice.